Hydroa vacciniforme lymphoproliferative disorders (HVLPD) fall within the clinical spectrum of chronic active ... Systemic HVLPD is high-risk for malignant transformation, requiring close follow-up to ...

Calquence is under clinical development by AstraZeneca and currently in Phase I for Coronavirus Disease 2019 (COVID-19).

Calquence is under clinical development by AstraZeneca and currently in Phase II for Graft Versus Host Disease (GVHD).

EBV infection of T or NK cells is also known in lymphoid malignancies such as extranodal NK/T-cell lymphoma (ENKL) and aggressive NK-cell leukemia (ANKL). The term EBV-associated T/NK-cell ...

Chronically immunocompromised patients have a markedly increased risk of developing lymphoproliferative ... Kaposi's sarcoma (KS), Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL).

EBV latency has been classified into three types: type I (Burkitt's lymphoma), in which only ... and type III (lymphoproliferative diseases in immunosuppressed individuals), in which five EBNAs ...

17, 2024 — Axi-cel CAR T targets the CD19 molecule on large B-cell lymphoma cells. The ZUMA-7 trial demonstrated that axi-cel reduced the risk of disease progression, the need for new therapy ...

The descriptive term AtLP may be used as an interim label when morphologic and molecular features are not sufficient to render a positive diagnosis of lymphoma. The development of AtLP may also ...

There are several subtypes of B-cell lymphoma, each with a distinct pathogenesis and disease course. 1 This article provides an overview of B-cell lymphoma so clinicians can pursue the correct ...

CURE® spoke with an expert about follicular lymphoma, a disease that is still considered incurable. There have been a number of advancements in the treatment of follicular lymphoma in 2024.

June 10, 2024 — Scientists have grown 'mini-guts' in the lab to help understand Crohn's disease, showing that 'switches' that modify DNA in gut cells play an ... Major Cause of Inflammatory ...